Relationship between patient characteristics at week 52 and the LDA sustainability outcomes at week 104 in the ADA discontinuation group (n=80)
| Sustained LDA | Failed LDA | p Value | |
|---|---|---|---|
| (n=64) | (n=16) | ||
| Sex: female, n (%) | 54 (84.4%) | 13 (81.3%) | 0.717 |
| Age (years) | 54.1±11.7 | 56.3±13.6 | 0.420 |
| Disease duration (years) | 1.2±0.3 | 1.3±0.4 | 0.824 |
| MTX dose (mg/w) | 7.1±1.8 | 7.4±2.2 | 0.650 |
| PSL: Use, n (%) | 14 (21.9%) | 6 (37.5%) | 0.211 |
| TJC28 | 0.7±1.4 | 2.2±3.0 | 0.001** |
| SJC28 | 0.4±0.9 | 0.7±1.1 | 0.139 |
| CRP (mg/dL) | 0.1±0.1 | 0.2±0.2 | <0.001*** |
| ESR (mm/h) | 18.0±12.8 | 20.7±14.0 | 0.330 |
| EGA | 6.7±6.7 | 10.7±7.4 | 0.040* |
| PGA | 7.0±8.2 | 13.1±17.1 | 0.087 |
| Pain VAS | 7.1±7.6 | 13.0±16.6 | 0.136 |
| DAS28-ESR | 2.2±0.7 | 3.0±0.7 | 0.001** |
| DAS28-CRP | 1.6±0.5 | 2.3±0.6 | <0.001*** |
| HAQ | 0.199±0.280 | 0.219±0.346 | 0.821 |
| Erosion | 6.9±7.0 | 11.8±21.7 | 0.317 |
| JSN | 7.2±11.4 | 14.1±22.8 | 0.064 |
| mTSS | 14.2±16.5 | 25.9±44.1 | 0.104 |
| MMP-3 (mg/mL) | 53.0±41.5 | 86.2±60.3 | 0.056 |
| RF (U/mL) | 40.7±45.5 | 52.4±78.6 | 0.605 |
| ACPA (U/ml) | 190.8±330.8 | 368.9±1288.9 | 0.348 |
Data are reported as means±SD, unless otherwise indicated. Statistical significance was assessed by Fisher's exact test for categorical data and the Wilcoxon rank sum test for continuous data.
*p<0.05, **p<0.01, ***p<0.001: Sustained LDA versus Failed LDA.
ACPA, anticyclic citrullinated peptide antibody; CRP, C reactive protein; DAS28, disease activity score 28; EGA, evaluator global assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; JSN, joint space narrowing; MMP-3, matrix metalloproteinase-3; mTSS, modified total sharp score; MTX, methotrexate; PGA, patient global assessment; PSL, prednisolone; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.